New PCR method for diagnosing Candida infections in ICU patients
Evaluation of the Effect of the Implementation of a Candida PCR Diagnosis Strategy on the Time Required to Obtain Results in Patients From Intensive Care Units With Suspected Systemic Invasive Candidiasis: Pilot Study
This study is testing a new quick test for Candida infections in ICU patients to see if it helps doctors start treatment faster than the usual blood tests.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse, Occitanie) |
| Trial ID | NCT04874441 on ClinicalTrials.gov |
What this trial studies
This study evaluates a new PCR-based diagnostic technique for invasive candidiasis in patients from intensive care units. The primary goal is to determine how quickly results can be obtained using this method compared to traditional blood cultures. By facilitating earlier antifungal treatment switches, the study aims to reduce the development of drug resistance and lower healthcare costs associated with antifungal therapies. Patients will be divided into two groups: one receiving standard blood culture diagnostics and the other utilizing the new PCR technique.
Who should consider this trial
Good fit: Ideal candidates are non-neutropenic patients in intensive care with suspected invasive candidiasis who have consented to participate.
Not a fit: Patients under guardianship, pregnant or breastfeeding individuals, and those not hospitalized in the Toulouse University Hospital ICU will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to faster diagnosis and treatment of invasive candidiasis, improving patient outcomes and reducing healthcare costs.
How similar studies have performed: Other studies have shown promise in using PCR techniques for rapid diagnosis of infections, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient affiliated or benefiting from a social protection system * Patient (or his/her trusted person) having given free and informed written consent to the investigating physician * Non-neutropenic patient hospitalised in the Toulouse University Hospital intensive care unit. * Patient with suspected invasive candidiasis for whom a blood culture for fungal infection diagnosis was taken and for whom an empirical treatment with echinocandin at an adapted dose was implemented. Exclusion Criteria: * Patients under guardianship or trusteeship, persons under court protection * Pregnant or breastfeeding patients.
Where this trial is running
Toulouse, Occitanie
- Uh Toulouse — Toulouse, Occitanie, France (Recruiting)
Study contacts
- Principal investigator: Pamela CHAUVIN, MD — University Hospital, Toulouse
- Study coordinator: Pamela CHAUVIN
- Email: chauvin.p@chu-toulouse.fr
- Phone: 05 67 69 04 09
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.